Iranian Company Exports Pharmaceutical Products to 9 Countries

Amir Esmayeel Saqafinia, the managing-director of the knowledge-based company, said that the synthesis of nitroglycerin pharmaceutical raw material, the mass-production of nitroglycerin continuous release tablets and knowledge-based iodofolic products are among the achievements of the company.

“We are one of the few pharmaceutical companies that succeeded in obtaining a GMP certificate for pharmaceutical products (general solids - dry powder suspension) by following the principles and standards of pharmaceutical product production,” he noted.

“Also, the production of nitroglycerin granules ready to be pressed and nitroglycerin soluble in ethanol and propylene glycol for injectable use and soluble in Miglyol for the production of sublingual pearls based on the latest PIC/S international standard from the Food and Drug Organization of the Ministry of Health are other activities of our company,” Saqafinia said.

“Our products have been exported to 9 countries, including Ukraine, Georgia, Lebanon, Armenia, Russia, Iraq, Vietnam, Afghanistan and the Philippines,” he added.

Earlier reports in August also said that an Iranian knowledge-based company had acquired the formulation of the production of medicines for rare diseases based on biotechnology and has managed to experts them to 15 countries.

“Most of these drugs are prescribed to treat certain patients with rare diseases. The technology used in these drugs is based on biological technologies,” said Mohammad Safariun, the CEO of the pharmaceutical company in an interview with local Iranian media.

He then said that ‘Factor VIII’ is the latest product of the company which is an essential blood clotting protein.

The active substance in Advate, octocog alfa (human coagulation factor VIII), is a substance that helps the blood to clot. Patients with haemophilia A lack factor VIII, and this causes blood clotting problems, such as bleeding in the joints, muscles or internal organs.

Safariun pointed to AryoSeven™ as a safe Iranian recombinant activated factor VII as the other product of their company. It is a man-made protein produced to replicate the naturally occurring activated factor VII (factor VIIa) in the body. It is used to stop bleeding of injuries for patients with hemophilia by helping the blood to clot. Factor VIIa is to be given only by or under the direct supervision of your doctor.

AryoSeven produced by the company is the first Iranian drug registered in Turkey.

AryoTrust (Trastuzumab) is a biosimilar product produced by the company with the generic name of Trastuzumab. AryoTrust is a recombinant DNA-derived humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2).

The other medince produced in the company is Stivant which is a recombinant monoclonal antibody.

Also Arylia as the other product of the knowledge-based company is used to treat Osteoporosis in postmenopausal women and in men at increased risk of fractures. Bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures and bone loss in females receiving aromatase inhibitor therapy for breast cancer.

He said a survey they had conducted on the AryoSeven or factor VII showed the complete satisfaction of patients with thwmedicine.

4155/v